Advanced prostate cancer therapy involves choosing among four next-generation androgen-receptor pathway inhibitors with overlapping indications across mHSPC, nmCRPC, and mCRPC settings. The sequencing of these agents with PARP inhibitors (for BRCA/HRR-mutant patients) and radioligand therapy is an area of active clinical debate and substantial promotional spend.
Data from CMS Open Payments (2023–2024) · last checked
These are the close-substitute branded therapies your oncologist may choose among for prostate cancer (advanced/mcrpc). Generic and biosimilar options may also be available depending on line of therapy.
Across all oncologists in our index (all cancer types), these are the companies making these prostate cancer (advanced/mcrpc) drugs, summed across their latest reported year of disclosures. Payments include both general and research categories; see methodology for the split.
| Manufacturer | Total disclosed to oncologists (latest year) |
|---|---|
| AstraZeneca | $11,913,894 |
| Pfizer | $8,033,132 |
| Merck | $5,435,449 |
| Novartis | $2,644,139 |
| Astellas | $1,725,342 |
| Bayer | $950,975 |
| Orion | $4,115 |
| Johnson & Johnson | $1,618 |
Active prostate cancer (advanced/mcrpc) trials in our database where one or more research-payment records (tied to the trial's NCT ID) are disclosed in CMS Open Payments. We show the disclosed principal investigators and amounts. The presence of research payments on a trial is expected — industry-funded clinical trials pay the physicians running them for site work — but knowing the scale gives you useful context.
Sponsor: Eli Lilly and Company · sponsor also appears in the payment records
$427,568
5
Sponsor: Northwestern University
$151,334
1
A financial relationship between a physician and a manufacturer is not, on its own, a problem — it is the expected context of modern drug development. The purpose of federal disclosure is to let you ask informed questions, not to make the decision for you.
Medical disclaimer: This page aggregates public federal data and is not medical advice. Drug choice for any individual patient depends on stage, biomarker profile, prior therapy, comorbidities, and patient preference — decisions that must be made with your licensed care team.
About the payment data: Figures are disclosed by manufacturers to CMS under the Physician Payments Sunshine Act (42 U.S.C. §1320a-7h). Presence of payments is not a conflict of interest. Physicians who believe a record is wrong file a correction through the CMS dispute process.
Sources: CMS Open Payments · ClinicalTrials.gov · Data fetched: 2026-04-21 · full methodology